Home Newsfeeds Barclays Maintains Overweight on eBay, Lowers Price Target to $56

Barclays Maintains Overweight on eBay, Lowers Price Target to $56

Barclays analyst Ross Sandler maintains eBay (NASDAQ:EBAY) with a Overweight and lowers the price target from $59 to $56.

byBenzinga Newsdesk

November 3, 2022

1 minute read

Barclays analyst Ross Sandler maintains eBay (NASDAQ:EBAY) with a Overweight and lowers the price target from $59 to $56.

POSaBIT Systems Reports Financial Performance In Q3 2023, Shows Resilience In Cannabis Payment Industry

By Joana Scopel

November 30, 8:42 PM

POSaBIT Systems Corporation (CSE: PBIT) (OTC: POSAF), a provider of payments infrastructure in the cannabis industry, has released its financial results for the third quarter of 2023, ending September 30, 2023.

CSE:PBIT

Cowen & Co. Maintains Outperform on Roper Technologies, Lowers Price Target to $500

By Benzinga Newsdesk

July 26, 8:17 AM

Cowen & Co. analyst Joseph Giordano maintains Roper Technologies (NYSE:ROP) with a Outperform and lowers the price target from $545 to $500.

ROP

Moody’s Warns Of ‘Rapid Deterioration’ In Banking Environment, Evaluates Comerica, Western Alliance And More

By Chris Katje

March 14, 1:02 PM

Risk assessment firm Moody’s Corporation (NYSE: MCO) is downgrading the outlook on the U.S.

CMA

ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths

By Vandana Singh

July 21, 11:56 AM

ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with previously untreated

ADCT

Barclays Maintains Overweight on eBay, Lowers Price Target to $56

Related Posts

POSaBIT Systems Reports Financial Performance In Q3 2023, Shows Resilience In Cannabis Payment Industry

Cowen & Co. Maintains Outperform on Roper Technologies, Lowers Price Target to $500

Moody’s Warns Of ‘Rapid Deterioration’ In Banking Environment, Evaluates Comerica, Western Alliance And More

ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths